Topic of the Month on ModernWeight: GLP-1 Success Stories!
Head to the Social Hub to share your success story or learn about others.
AOMs in the News
This Week's Featured Post
Featured Post: Breaking the Stigma: GLP-1s and Workplace Wellness
Link: Fortune Article
In the workplace, discussing weight loss and medications like GLP-1s can be taboo. However, with the rising popularity of these treatments, more people are confronting the stigma associated with using them. Melissa Baird, COO of Hims & Hers Health, openly shares her journey with GLP-1s, emphasizing the importance of breaking down these barriers. This week’s featured post delves into how GLP-1s reshape conversations around weight and health in professional settings.
Melissa Baird's candid discussion about her personal experience with GLP-1s highlights the stigma many face when using these medications in the workplace. With a family history of obesity and chronic conditions, Baird turned to GLP-1s as part of her weight management journey. She openly shares her story to help dispel the myths surrounding weight loss drugs and encourage others to prioritize their health without fear of judgment. As GLP-1s continue to gain popularity, Baird's story serves as a reminder that weight management is a personal journey and not a failure of willpower.
Why it matters: The conversation around GLP-1s in the workplace reflects broader societal attitudes toward weight loss and health. By openly discussing her experience, Baird is helping to break the stigma associated with these medications and promote a more supportive environment for those seeking to improve their health. As GLP-1s become more prevalent, it's essential to challenge misconceptions and create a culture of understanding and acceptance in both personal and professional settings.
Weight Loss Drugs Alone Are Not Enough for Health Goals
Link: MedicalXpress Article
While GLP-1 drugs are highly effective for weight loss, they are not a standalone solution for achieving overall health goals. Researchers from University College London emphasize the importance of a multidisciplinary approach that includes psychological, surgical, and dietary support. The editorial in Nutrition Bulletin highlights that GLP-1 drugs should be part of a broader strategy that addresses the complex nature of obesity.
Why it matters: Relying solely on weight-loss drugs without addressing underlying behavioral, psychological, and dietary factors can lead to unintended consequences. A comprehensive, multidisciplinary approach ensures patients achieve sustainable, long-term health outcomes. This reinforces the need for a well-rounded treatment plan that includes more than just medication.
Ricezempic: The TikTok Trend Mimicking GLP-1s
Link: Healthline Article
A new trend on TikTok, dubbed "Ricezempic," claims to mimic the effects of GLP-1 drugs like Ozempic using rice water. Proponents of this homemade remedy believe that resistant starches in rice water can suppress appetite and promote weight loss. However, health experts warn that while resistant starches may contribute to feelings of fullness, Ricezempic is not a viable weight-loss solution.
Why it matters: The rise of trends like Ricezempic highlights the ongoing search for quick fixes in weight loss. However, these trends can be misleading and may divert people from evidence-based treatments that are proven to work. It's crucial to approach such trends with skepticism and prioritize scientifically validated approaches to weight management.
How GLP-1 in the Brain's Smell Center Influences Insulin and Energy Balance
Link: Nature.com Article
This study explores the role of GLP-1 (glucagon-like peptide-1) in the olfactory bulb (OB) and its impact on insulin secretion. Researchers discovered that activating GLP-1 receptors in the OB of mice stimulates insulin release, improves glucose tolerance, and reduces food intake. The mechanism involves a neural circuit that modulates sympathetic nervous system activity through the paraventricular nucleus of the hypothalamus. The findings suggest that GLP-1 signaling in the OB plays a critical role in energy balance and glucose homeostasis, offering potential insights for treating metabolic disorders like obesity and diabetes.
Why it matters: This research highlights a novel neural mechanism by which GLP-1 can regulate insulin secretion and energy balance. Understanding these pathways may open new therapeutic approaches for managing metabolic conditions such as obesity and diabetes, expanding the pharmacological potential of GLP-1-based treatments.
Compounded GLP-1 Drugs: Ozempic and Wegovy Overdoses on the Rise
Link: Healthline Article
Overdoses related to compounded forms of GLP-1 drugs like Ozempic and Wegovy are becoming more common. The FDA has issued warnings about incorrect dosing, particularly with unapproved formulations. Symptoms of overdose include extreme diarrhea and vomiting, often requiring hospitalization.
Why it matters: As the popularity of GLP-1 drugs increases, so do the risks associated with improper use, especially with compounded formulations. Patients need to be aware of the dangers of incorrect dosing and seek professional guidance to avoid potentially life-threatening complications.
Ozempic Insurance Coverage: What You Need to Know
Link: Healthline Article
New research reveals that the majority of GLP-1 prescriptions in the United States are covered by commercial insurance, while coverage is significantly lower for Medicare and Medicaid recipients. The study highlights disparities in access to these medications, with Medicare Part D and Medicaid accounting for a much smaller share of prescription fills. The findings underscore the challenges faced by those with public insurance in obtaining GLP-1 drugs.
Why it matters: The disparity in insurance coverage for GLP-1 medications points to a larger issue of unequal access to treatment. With commercial insurance covering the majority of prescriptions, those relying on public insurance may face significant barriers in accessing these life-changing medications. Understanding these coverage trends is essential for addressing inequities in healthcare.
Expert Tweet of the Week
From @CNBCFastMoney
"Checking GLP-1 drug insurance coverage just got a little easier thanks to a new tool from @ro. CEO
@ZReitano explains how it works. He also gives his read on the blockbuster obesity drug market."
Related Video: CNBC Video
---
Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.
Want to receive this newsletter in your inbox weekly? Create a profile!
Comments